Parkinson’s disease (PD) affects an estimated 10 million men and women worldwide. Women have been shown to have a lower risk of developing PD, and research suggests that there are differences in the way that men and women experience Parkinson’s. Studies indicate that women diagnosed with PD report different symptoms, more often report side effects and changes in their symptoms throughout the day (“fluctuations”) and receive lower quality healthcare than men.
Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to A surgical treatment for Parkinson's disease.
Exercise is an important part of healthy living for everyone. For people with Parkinson’s, exercise is more than healthy: it is a vital component to maintaining balance, mobility and the ability to perform activities of daily living.
A surprising fact about A surgical treatment for Parkinson's disease. A special wire (lead) is inserted into a specific area of the brain responsible for movement. The lead is connected to a pacemaker-like device implanted in the chest region.
We are blessed to have the terrific and free Parkinson's Foundation 1-800-4PD-INFO Helpline staffed by nurses and social workers with experience in the field. Recently, many people have called the Helpline after seeing a video declaring focused ultrasound therapy as “the scalpel-less cure for Parkinson’s disease.” The Helpline staff thought it important to objectively explore this therapy and discuss whether it is indeed a scalpel-less cure.
This class of PD medications includes entacapone (Comtan®) and tolcapone (Tasmar®). They have no direct effect on PD symptoms, but are used to prolong the effect of levodopa by blocking its metabolism. An enzyme that inactivates levodopa in the body before it gets to the brain.
One of the common dreams shared by Parkinson’s disease patients around the globe is the possibility of living a pill free existence, and one year ago we shared the news of a therapy coming to the United States with the possibility to make this a reality for a select group of patients. This month we will update the previous blog post from 2014, and bring to you all of the information you need to know about the therapy. The therapy has received a full FDA approval and
In September 2012, the What’s Hot in Parkinson’s Disease? blog featured a new therapy that at that time had entered into human testing. The Austrian company AFFiRiS A.G.
There has been a recent and evolving media blitz concerning the potential use of medical marijuana (tetrahydrocannabinol, THC) among the Parkinson’s disease (PD) community. All of the attention to marijuana has been largely a result of multiple states passing legislation to legalize and to regulate the drug, or to alternatively make it available for select medical diagnoses.